EVALUATION OF OSELTAMIVIR AND FAVIPIRAVIR ON CLINICAL OUTCOMES AND LENGTH OF STAY IN COVID-19 PATIENTS AT FATMAWATI GENERAL HOSPITAL JAKARTA

Mareoza Ayutri; Retnosari Andrajati; Ahmad Subhan

doi:10.22159/ajpcr.2022.v15i10.45801

Authors

Mareoza Ayutri Department of Clinical Pharmacy, Faculty of Pharmacy, University of Indonesia, Depok, West Java, Indonesia.
Retnosari Andrajati Department of Clinical Pharmacy, Faculty of Pharmacy, University of Indonesia, Depok, West Java, Indonesia.
Ahmad Subhan Department of Pharmacy, Fatmawati General Hospital, Jakarta, Indonesia.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i10.45801

Keywords:

Clinical outcome, Covid-19, Favipiravir, Oseltamivir, Length of Stay

Abstract

Objectives: This study aimed to evaluate the effect of oseltamivir and favipiravir in patients with confirmed COVID-19 on clinical outcomes and length of stay at Farmawati General Hospital, Jakarta.

Methods: The cross-sectional study was conducted at Fatmawati General Hospital, Jakarta. The study sample consisted of 114 patients who met the inclusion and exclusion criteria from March to October 2020. Data were collected retrospectively using medical record data.

Results: The result showed that 98 patients (86.0%) received oseltamivir, while 16 patients (14.0%) received favipiravir in this study. The mortality rate was 11.4% (13 patients), while the recovered was 88.6% (103 patients). Patients who had LoS (Length of Stay) of ≤14 days were 58.8%, while patients with LoS >14 days were 41.2%. In bivariate analysis, antivirals (oseltamivir and favipiravir) effect on clinical outcome was not statistically significant (p=0.690; OR=0.478; CI 95%=0.058–3.950). Likewise, the association between antivirals and LoS was also not statistically significant (p=0.852; OR=0.767; CI 95%=0.251–2.342).

Conclusion: Antivirals were not significantly associated with clinical outcomes and length of stays in COVID-19 patients.

Downloads

Download data is not yet available.

References

Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A, et al. Covid-19 Treatment Protocol. 1st ed. Perhimpunan Dokter Paru Indonesia (PDPI). Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI), Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN). Jakarta: Ikatan Dokter Anak Indonesia; 2020.

World Health Organization. WHO Coronavirus (COVID-19). Geneva: World Health Organization; 2020. Available from: https://www. covid19.who.int [Last accessed on 2020 Sep 30].

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 2020;323:1824-36.

Peckham H, De Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun 2020;11:6317.

Guo A, Lu J, Tan H, Kuang Z, Luo Y, Yang T, et al. Risk factors on admission associated with hospital length of stay in patients with COVID-19: A retrospective cohort study. Sci Rep 2021;11:7310.

DKI Jakarta Provincial Government. Data Monitoring COVID-19 Jakarta. DKI Jakarta Provincial Government. Available from: https://www.corona. jakartagoid/id/data-pemantauan [Last accessed on 2021 May ].

Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis 2020;20:e238-44.

Ya’qoub L, Elgendy IY, Pepine CJ. Sex and gender differences in COVID-19: More to be learned!. Am Heart J Plus 2013;3:100011.

Ramatillah DL, Isnaini S. Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. PLoS One 2021;16:e0250147.

Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis 2021;103:62-71.

Dabbous HM, El-Sayed MH, El Assal G, Elghazaly H, Ebeid FF, Sherief AF, et al. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Sci Rep 2021;11:7282.

Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, Carl CA, et al. COVID-19 length of hospital stay: A systematic review and data synthesis. BMC Med 2020;18:270.

WHO Solidarity Trials, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Karim QA, et al. Repurposed antiviral drugs for Covid- 19-interim WHO solidarity trial results. N Engl J Med 2021;384:497-51.